Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Ann Partridge, MD, MPH
Pre-menopausal breast cancer survivors who were treated with
chemotherapy following surgery were more likely to have diminished
ovarian reserve — the capacity of the ovaries to provide eggs capable of
being fertilized — compared to women who have never had breast cancer,
according to a study led by Dana-Farber Cancer Institute investigators.
Their findings will be presented at the annual meeting of the American
Society of Clinical Oncology (ASCO), May 30 – June 3, in Chicago.
The researchers analyzed markers of ovarian reserve in 20
premenopausal breast cancer patients who had been treated with adjuvant
chemotherapy, who were one or more years out from their diagnosis, and
who had no evidence of recurrence. This group was compared with a
"control" group of 20 like-aged women without a history of the disease.
The evaluation involved five tests conducted two, three or four days
after a menstrual cycle to assess the ovaries' physical condition,
hormone levels and a compound involved in the menstrual cycle. In four
of the five tests, the breast cancer survivors had a worse ovarian
reserve than did the control group. The other test showed no major
difference between the two groups.
"These findings may have important implications for women who are
interested in having children after receiving chemotherapy," said Ann Partridge, MD, MPH, of Dana-Farber, who led the study. "Studies that
track breast cancer survivors following treatment are needed to
determine the predictive value of these tests for pregnancy."
The results (abstract 9571) will be presented during a poster session on Saturday, May 31, 2 – 6 p.m., South Building, Hall A1.
The study's co-authors are Kathryn Ruddy, MD, Shari Gelber, Eric
Winer, MD, and Meghan Meyer of Dana-Farber, Boston; Lidia Schapira, MD,
of Massachusetts General Hospital, Boston; and Elizabeth Ginsburg, MD,
senior author, and Mary Abusief, MD, of Brigham and Women's Hospital,
Financial support for the study was provided by the Lance Armstrong Foundation.
Dana-Farber Cancer Institute (www.dana-farber.org)
is a principal teaching affiliate of the Harvard Medical School and is
among the leading cancer research and care centers in the United States.
It is a founding member of the Dana-Farber/Harvard Cancer Center
(DF/HCC), designated a comprehensive cancer center by the National